Ischemic cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnostic and clinical management

Albakri, Aref

doi:10.15761/bem.1000151

Cited by 4 publications

(2 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is perceivable that these risk factors would also explain a relatively higher burden of CAD found in the group with mixed CMP compared to NICM. 13,14 This finding is also consistent with the studies on idiopathic DCM with coexisting CAD. [6][7][8] While the proportion of device therapies and device shocks in mixed CMP falls in an intermediate category between ICM and NICM, the recorded minimum VT cycle length is comparable to patients with ICM.…”

Section: The Phenotype Of Mixed Cmpsupporting

confidence: 91%

Characteristics of the Phenotype of Mixed Cardiomyopathy in Patients with Implantable Cardioverter-Defibrillators

Pathak

Raja

Samarawickrema³

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: The prognosis of mixed cardiomyopathy (CMP) in patients with implanted cardioverter-defibrillators (ICDs) has not been investigated. We aim to study the demographic, clinical, device therapies and survival characteristics of mixed CMP in a cohort of patients implanted with a defibrillator. Methods: The term mixed CMP was used to categorise patients with impaired left ventricular ejection fraction attributed to documented non-ischemic triggers with concomitant moderate coronary artery disease. This is a single center observational cohort of 526 patients with a mean follow-up 8.7±3.5 years. Results: There were 42.5% patients with ischemic cardiomyopathy (ICM), 26.9% with non-ischemic cardiomyopathy (NICM) and 30.6% with mixed CMP. Mixed CMP, compared to NICM, was associated with higher mean age (69.1±9.6 years), atrial fibrillation (55.3%) and greater incidence of comorbidities. The proportion of patients with mixed CMP receiving device shocks was 23.6% compared to 18.4% in NICM and 27% in ICM. The VT cycle length recorded in mixed CMP (281.6 ± 43.1ms) was comparable with ICM (282.5 ± 44ms; p=0.9) and lesser than NICM (297.7 ± 48.7ms; p=0.1). All-cause mortality in mixed CMP (21.1%) was similar to ICM (20.1%; p=0.8) and higher than NICM (15.6%; p=0.2). Kaplan-Meier curves revealed hazards of 1.57 (95% CI: 0.91, 2.68) for mixed CMP compared to NICM. Conclusion: In a cohort of patients with ICD, the group with mixed CMP represent a phenotype predominantly comprised of elderly with higher incidence of comorbidities. Mixed CMP resembles ICM in terms of number of device shocks and VT cycle length. Long-term prognosis of patients with mixed CMP is worse than NICM and similar to ICM.

show abstract

Section: The Phenotype Of Mixed Cmpsupporting

confidence: 91%

Characteristics of the Phenotype of Mixed Cardiomyopathy in Patients with Implantable Cardioverter-Defibrillators

Pathak

Raja

Samarawickrema³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The etiological factors of HF syndrome are often difficult to discern and vary (5,6), with dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) being among the main causes of HF in Western countries. ICM is defined by an imbalance between myocardial oxygen demand and supply resulting in myocyte loss and ventricular failure (7), while DCM is characterized by left ventricular dilation and subsequent contractile dysfunction (8).…”

Section: Introductionmentioning

confidence: 99%

Multi-omics integration to identify the genetic expression and protein signature of dilated and ischemic cardiomyopathy

Portokallidou

Dovrolis²,

Ragia³

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

IntroductionHeart failure (HF) is a complex clinical syndrome leading to high morbidity. In this study, we aimed to identify the gene expression and protein signature of HF main causes, namely dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM).MethodsOmics data were accessed through GEO repository for transcriptomic and PRIDE repository for proteomic datasets. Sets of differentially expressed genes and proteins comprising DCM (DiSig) and ICM (IsSig) signatures were analyzed by a multilayered bioinformatics approach. Enrichment analysis via the Gene Ontology was performed through the Metascape platform to explore biological pathways. Protein-protein interaction networks were analyzed via STRING db and Network Analyst.ResultsIntersection of transcriptomic and proteomic analysis showed 10 differentially expressed genes/proteins in DiSig (AEBP1, CA3, HBA2, HBB, HSPA2, MYH6, SERPINA3, SOD3, THBS4, UCHL1) and 15 differentially expressed genes/proteins in IsSig (AEBP1, APOA1, BGN, CA3, CFH, COL14A1, HBA2, HBB, HSPA2, LTBP2, LUM, MFAP4, SOD3, THBS4, UCHL1). Common and distinct biological pathways between DiSig and IsSig were retrieved, allowing for their molecular characterization. Extracellular matrix organization, cellular response to stress and transforming growth factor-beta were common between two subphenotypes. Muscle tissue development was dysregulated solely in DiSig, while immune cells activation and migration in IsSig.DiscussionOur bioinformatics approach sheds light on the molecular background of HF etiopathology showing molecular similarities as well as distinct expression differences between DCM and ICM. DiSig and IsSig encompass an array of “cross-validated” genes at both transcriptomic and proteomic level, which can serve as novel pharmacological targets and possible diagnostic biomarkers.

show abstract

Ischemic cardiomyopathy: epidemiology, pathophysiology, outcomes, and therapeutic options

Pastena,

Frye,

et al. 2023

Heart Fail Rev

View full text Add to dashboard Cite

Ischemic cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnostic and clinical management

Cited by 4 publications

References 83 publications

Characteristics of the Phenotype of Mixed Cardiomyopathy in Patients with Implantable Cardioverter-Defibrillators

Characteristics of the Phenotype of Mixed Cardiomyopathy in Patients with Implantable Cardioverter-Defibrillators

Multi-omics integration to identify the genetic expression and protein signature of dilated and ischemic cardiomyopathy

Ischemic cardiomyopathy: epidemiology, pathophysiology, outcomes, and therapeutic options

Contact Info

Product

Resources

About